Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.
about
Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational StudiesGuidelines on the management of atrial fibrillation in the emergency department: a critical appraisal.Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.The involvement of pharmacies in the screening of undiagnosed atrial fibrillation.
P2860
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Direct oral anticoagulants in ...... o the general population? Yes.
@ast
Direct oral anticoagulants in ...... o the general population? Yes.
@en
type
label
Direct oral anticoagulants in ...... o the general population? Yes.
@ast
Direct oral anticoagulants in ...... o the general population? Yes.
@en
prefLabel
Direct oral anticoagulants in ...... o the general population? Yes.
@ast
Direct oral anticoagulants in ...... o the general population? Yes.
@en
P2860
P1476
Direct oral anticoagulants in ...... to the general population? Yes
@en
P2093
Nicoletta Riva
Walter Ageno
P2860
P2888
P304
P356
10.1007/S11739-015-1277-6
P577
2015-07-08T00:00:00Z